Saniona AB (publ)
SANION.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.32B
Close$
Share Statistics
| Market cap | $1.32 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.21 |
| Beta | 1.16 |
| Outstanding Shares | 138,030,134 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 7.14 |
|---|---|
| PEG | 4.41 |
| Price to Sales | 3.19 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$4.55 M
Average shareholder expectationNext Earnings Call
Expected Date
November 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$5.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Saniona AB (publ)
44 employees
CEO: Thomas Feldthus Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous ...